MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial
The suits contend MoonLake overstated sonelokimab’s Nanobody advantages over BIMZELX after trial data coincided with a near-90% one-day share drop.
Overview
- Multiple actions and investigations are pending in the Southern District of New York, including Bridgewood v. MoonLake Immunotherapeutics, No. 1:25-cv-08500, and Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612.
- Plaintiffs allege MoonLake misled investors by claiming SLK’s Nanobody structure would deliver superior clinical benefit versus monoclonal antibody BIMZELX, despite both targeting IL‑17A and IL‑17F.
- Notices cite claims under Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5 tied to statements made during the March 10, 2024 to September 29, 2025 class period.
- The litigation follows MoonLake’s September 28, 2025 Phase 3 VELA disclosure showing disappointing results, including VELA‑2 missing its primary endpoint, which was followed by an almost 90% stock decline the next trading day.
- Hagens Berman, Bleichmar Fonti & Auld, Berger Montague, Levi & Korsinsky, Rosen Law Firm, and Howard G. Smith are soliciting investors and reminding them that lead‑plaintiff motions are due December 15, 2025, with cases at an early stage and no class certified.